Crossmark

High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltration

Crossref DOI link: https://doi.org/10.1007/s10549-024-07515-3

Published Online: 2024-11-23

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Matossian, Margarite D.

Shiang, Christine

Dolcen, Deniz Nesli

Dreyer, Marie

Hatogai, Ken

Hall, Katie

Saha, Poornima

Biernacka, Anna

Sweis, Randy F.

Karrison, Theodore

Chen, Nan

Nanda, Rita

Conzen, Suzanne D.
Funding

Funding for this research was provided by:

National Institutes of Health (P30CA014599-42S2)

Cancer Prevention and Research Institute of Texas (RR190037)
License Information

Text and Data Mining valid from 2024-11-23

Version of Record valid from 2024-11-23
More Information

Article History

Received: 30 August 2024

Accepted: 3 October 2024

First Online: 23 November 2024

Declarations

:

: Margarite Matossian, Christine Shiang, Deniz Nesli Dolcen, Ken Hatogai, Katie Hall, Theodore Karrison and Anna Biernacka, Poornima Saha declare they have no financial interests. Randy F. Sweis reports consulting fees from, Astellas, AstraZeneca, Aveo, BMS, EMD Serono, Editas, Exelixis, Gilead, Eisai, Janssen, Loxo, Lilly, Mirati, Pfizer, Silverback, and Seattle Genetics. Randy F. Sweis reports research support (to institution) from Ascendis, ALX Oncology, Astellas, AstraZeneca, Bayer, BMS, CytomX, Eisai, Genentech/Roche, Gilead, Immunocore, Jounce, Loxo, Lilly, Merck, Moderna, Mirati, Novartis, Pfizer, Pionyr, Pyxis, Scholar Rock, QED Therapeutics. Randy F. Sweis reports the following patents: Neoantigens in Cancer, PCT/US2020/031357. Rita Nanda has served on advisory boards for Astrazeneca, BeyondSpring, Daiichi Sankyo, Exact Sciences, Fujifilm, GE, Gilead, Guardant Health, Infinity, iTeos, Merck, Moderna, Novartis, OBI, Oncosec, Pfizer, Sanofi, Seagen, Stemline, and she has research funding from Arvinas, AstraZeneca, BMS, Corcept Therapeutics, Genentech/Roche, Gilead, GSK, Merck, Novartis, OBI Pharma, OncoSec, Pfizer, Relay, Seattle Genetics, Sun Pharma, Taiho. Nan Chen has received consultant fees from Stemline Therapeutics, Guardant Health, Novartis, and Seagen. Nan Chen has received institutional research funding from Eli Lilly. S.D. Conzen is a co-inventor of patents issued to The University of Chicago for methods and compositions related to GR antagonists and breast cancer.

Document is current

Any future updates will be listed below